Table 5 |
|||
|
Adverse events reported by at least 5% of patients (overall and by previous treatment) |
|||
|
Treatment in previous study |
|||
|
OROS® hydromorphone (n = 35) |
CR morphine (n = 33) |
Overall (n = 68) |
|
|
Adverse event |
Number (%) of patients with adverse event |
||
|
|
|||
|
Nausea |
13 (37.1) |
11 (33.3) |
24 (35.3) |
|
Constipation |
13 (37.1) |
9 (27.3) |
22 (32.4) |
|
Vomiting |
8 (22.9) |
7 (21.2) |
15 (22.1) |
|
Anaemia |
7 (20.0) |
5 (15.2) |
12 (17.6) |
|
Peripheral oedema |
5 (14.3) |
6 (18.2) |
11 (16.2) |
|
Dyspnoea |
4 (11.4) |
5 (15.2) |
9 (13.2) |
|
Asthenia |
4 (11.4) |
5 (15.2) |
9 (13.2) |
|
Somnolence |
6 (17.1) |
2 (6.1) |
8 (11.8) |
|
Disease progression |
6 (17.1) |
2 (6.1) |
8 (11.8) |
|
Urinary tract infection |
4 (11.4) |
3 (9.1) |
7 (10.3) |
|
Headache |
4 (11.4) |
2 (6.1) |
6 (8.8) |
|
Diarrhoea |
5 (14.3) |
1 (3.0) |
6 (8.8) |
|
Back pain |
4 (11.4) |
1 (3.0) |
5 (7.4) |
|
Anorexia |
3 (8.6) |
2 (6.1) |
5 (7.4) |
|
Oedema |
3 (8.6) |
2 (6.1) |
5 (7.4) |
|
Dehydration |
0 |
5 (15.2) |
5 (7.4) |
|
Confusional state |
4 (11.4) |
1 (3.0) |
5 (7.4) |
|
Pyrexia |
4 (11.4) |
1 (3.0) |
5 (7.4) |
|
Pain |
1 (2.9) |
4 (12.1) |
5 (7.4) |
|
Insomnia |
1 (2.9) |
3 (9.1) |
4 (5.9) |
|
Dry mouth |
2 (5.7) |
2 (6.1) |
4 (5.9) |
|
Anxiety |
3 (8.6) |
1 (3.0) |
4 (5.9) |
|
|
|||
|
CR, controlled-release |
|||
|
Hanna et al. BMC Palliative Care 2009 8:14 doi:10.1186/1472-684X-8-14 |
|||
